China’s Dual GCG/GLP-1 Breakthrough, Innogen’s 2026 Goal, Zepbound’s Korea Launch & More
In this week’s Obesity Updates, we spotlight the most compelling developments shaping the obesity treatment landscape—from first-in-class dual agonists and oral GLP-1 innovations to pricing battles and biotech surges.
🔬 Key Highlights This Week:
🇨🇳 Mazdutide approved in China—world’s first dual GLP-1/glucagon drug
🧪 Innogen targets 2026 finish for efsubaglutide trials
❤️ China’s obesity drugs show added heart and liver benefits
🇰🇷 Lilly’s Zepbound to launch in Korea by late August
🌐 Ascletis starts U.S. trial for oral GLP-1 ASC30
📈 G2GBIO stock jumps on monthly GLP-1 delivery tech
Whether you’re a researcher, investor, or life sciences leader, this episode delivers a concise, expert-curated view of the obesity innovation landscape.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #Mazdutide #Zepbound #Innogen #G2GBIO #ClinicalTrials #WeightLossDrugs #ChinaBiotech #KoreaPharma #LucidQuest #MetabolicHealth #BiotechNews #PharmaInnovation #ObesityTreatment #HealthcareConsulting